{"entity":{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","aka":[],"tldr":"POINT Biopharma developed radioactive medicines that home in on prostate cancer and neuroendocrine tumours, and built a large manufacturing campus in Indianapolis. Eli Lilly bought the company at the end of 2023.","summary":"POINT Biopharma Global Inc. (formerly Nasdaq: PNT) was an Indianapolis radiopharmaceutical company with late-stage radioligand therapies: PNT2002, a PSMA-targeted therapy for metastatic castration-resistant prostate cancer after progression on hormonal treatment, and PNT2003, a somatostatin receptor (SSTR)-targeted therapy for gastroenteropancreatic neuroendocrine tumours, both partnered with Lantheus outside certain Asian territories, plus earlier clinical and preclinical programmes. It operated a 180,000 square foot radiopharmaceutical manufacturing campus in Indianapolis and an R&D centre in Toronto. On 2 October 2023 Eli Lilly agreed to acquire POINT through a cash tender offer of USD 12.50 per share, and the merger was completed in late December 2023; the company website now redirects to lilly.com.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lilly.com/"},{"label":"Form 8-K: merger agreement with Eli Lilly","url":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_8k.htm"},{"label":"Lilly press release (8-K exhibit 99.4)","url":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_ex99-4.htm"},{"label":"Form 8-K: completion of merger","url":"https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/d594310d8k.htm"}],"tags":[],"related":[],"cancers":["prostate","neuroendocrine"],"sections":["radiopharma"],"technologies":["radioligand-therapy"],"targets":["psma","sstr2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["pointbiopharma.com redirects to lilly.com, recorded as the website. Deal value and pipeline details come from the Lilly press release filed as exhibit 99.4 to POINT's 8-K of 3 October 2023."],"hq":"Indianapolis, IN","country":"US","companyType":"radiopharma","website":"https://www.lilly.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2023,"amountUsd":1400000000,"source":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_ex99-4.htm","note":"Cash tender offer at USD 12.50 per share, an aggregate of approximately USD 1.4 billion, under a merger agreement dated 2 October 2023; completion reported in an 8-K filed 27 December 2023"}],"acquiredBy":"eli-lilly"},"route":"/companies/point-biopharma/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}